Author

H. Rizvi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Chow· 3 shared C. M. Rudin· 3 shared M. D. Hellmann· 3 shared T. Merghoub· 3 shared A. J. Plodkowski· 2 shared A. Quintanal-Villalonga· 2 shared E. de Stanchina· 2 shared J. D. Wolchok· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Chow

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A Versatile Photocrosslinkable Silicone Composite for 3D Printing Applications

M. A. Alioglu, Y. O. Yilmaz, E. M. Gerhard, V. Pal, D. Gupta, H. Rizvi, I. T. Ozbolat

This paper introduces a versatile, photocrosslinkable silicone composite for 3D printing, demonstrating its use as a support bath and extrudable ink for creating complex microfluidic devices and biomedical constructs.

bioRxiv · Jul 17, 2023Bioengineering

A CD24+CD271+ Melanoma Cancer Stem Cell Possesses Hybrid Characteristics of its Single Marker Counterparts and Promotes Invasion and Therapeutic Resistance

O. Knowles, P. Doldan, I. Hillier-Richardson, S. Lunt, G. Youssef, L. Gammon, I. C. Mackenzie, M. P. Philpott, H. Rizvi, D. Bergamaschi, C. A. Harwood, A. Biddle

The paper identifies a CD24+CD271+ melanoma sub-population with hybrid characteristics and enhanced invasive and therapeutic resistance properties.

bioRxiv · Jun 7, 2023Cancer Biology

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

A. Chow, F. Z. Uddin, L. Mangarin, H. Rizvi, A. Dobrin, S. E. Tischfield, A. Quintanal-Villalonga, J. M. Chan, N. S. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, M. Liu, R. Landau, , C. M. Rudin

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

bioRxiv · Jan 24, 2022 · PreprintImmunology

Regional and clonal T cell dynamics at single cell resolution in immune checkpoint blockade

J. A. Pai, A. Chow, J. Sauter, M. Mattar, H. Rizvi, H. J. Woo, N. Shah, F. Uddin, A. Quintanal-Villalonga, J. M. Chan, P. Manoj, V. Allaj, M. Baine, J. E. Chaft, A. J. Plodkowski, , M. D. Hellmann

This study uses scTCR/RNA-seq to analyze T cell dynamics in lung cancer patients before and after ICB, finding regional heterogeneity and clonal persistence associated with clinical responses.

bioRxiv · Sep 27, 2021 · PreprintImmunology

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

D. Memon, H. Rizvi, G. Fromm, J. Lihm, A. J. Schoenfeld, J. L. Sauter, J. Luo, A. Chow, U. K. Bhanot, C. McCarthy, D. Ye, C. M. Vanderbilt, C. Liu, M. Abu-Akeel, A. J. Plodkowski, , M. D. Hellmann

This study characterizes clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC, identifying persistent inflammation and dysfunctional IFN signaling as key features.

bioRxiv · Jul 21, 2021Cancer Biology

Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

C. Li, W.-Y. Lin, H. Rizvi, H. Cai, C. D. McFarland, Z. N. Rogers, M. Yousefi, I. P. Winters, C. M. Rudin, D. Petrov, M. M. Winslow

The paper uses a quantitative platform and statistical methods to map pharmacogenomic responses in lung cancer, revealing complex genotype-specific therapeutic interactions.

bioRxiv · Jan 28, 2020Cancer Biology